SVNT Share Price

Open 47.25 Change Price %
High 47.25 1 Day 1.00 2.16
Low 47.25 1 Week 0.50 1.07
Close 47.25 1 Month 3.01 6.80
Volume 4600 1 Year 47.19 78650.00
52 Week High 48.20
52 Week Low 14.75
SVNT Important Levels
Resistance 2 47.25
Resistance 1 47.25
Pivot 47.25
Support 1 47.25
Support 2 47.25
NASDAQ USA Most Active Stocks
ASTI 0.00 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
DRYS 1.01 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
ACAS 17.99 0.39%
More..
NASDAQ USA Top Gainers Stocks
CPSL 0.10 66.67%
LOCM 0.09 50.00%
GLBS 9.70 31.79%
LTRE 2.85 29.55%
ETRM 7.96 29.22%
INFI 2.00 29.03%
QKLS 0.14 27.27%
PRKR 2.57 26.60%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
More..
NASDAQ USA Top Losers Stocks
HEAT 0.00 -100.00%
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
AMCF 0.03 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
More..

Savient Pharmaceuticals Inc (NASDAQ: SVNT)

SVNT Technical Analysis 5
As on 20th Jan 2017 SVNT Share Price closed @ 47.25 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 12.92 & Strong Buy for SHORT-TERM with Stoploss of 34.55 we also expect STOCK to react on Following IMPORTANT LEVELS.
SVNT Target for January
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
Savient Pharmaceuticals Inc ( NASDAQ USA Symbol : SVNT )
Sector : Consumer Durables Specialty Chemicals And Other Stocks in Same Sector
SVNT
47.25 1.00 (2.16 %)
LT : Strong Buy
ST : Strong Buy
SVNT Other Details
Segment EQ
Market Capital 108615704.00
Sector Consumer Durables Specialty Chemicals
Industry
Offical website
SVNT Address
SVNT
N/A
Interactive Technical Analysis Chart Savient Pharmaceuticals Inc ( SVNT NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Savient Pharmaceuticals Inc
SVNT Business Profile
Savient Pharmaceuticals, Inc. (Savient), incorporated in 1980, is a specialty biopharmaceutical company focused on commercializing KRYSTEXXA (pegloticase) in the United States and completing the development and seeking regulatory approval outside of the United States for KRYSTEXXA, particularly in the European Union. The Company also sells and distributes branded and generic versions of oxandrolone, a drug used to promote weight gain following involuntary weight loss. In October 2013, the Company announced that it has elected to file voluntary petitions under Chapter 11 of the Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware (the Court). Effective January 10, 2014, Crealta Pharmaceuticals LLC, a majority owned unit of GTCR LLC acquired Savient Pharmaceuticals Inc.